SCHEMBL6715689

SCHEMBL6715689

COc1ccc(NC(=S)NC(C(=O)Nc2cccc(C)c2)c2ccccc2)c([N+](=O)[O-])c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.59
MEN1 O00255 8/20 0.59
KMT2A Q03164 8/20 0.59
ALDH1A1 P00352 8/20 0.59
NPSR1 Q6W5P4 4/20 0.59
TP53 P04637 2/20 0.53
CYP2C19 P33261 2/20 0.53
CYP2C9 P11712 1/20 0.53
RAB9A P51151 4/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
NPC1 O15118 3/20 0.52
MAPK1 P28482 1/20 0.52
TDP1 Q9NUW8 2/20 0.51
POLB P06746 1/20 0.51
OPRK1 P41145 1/20 0.51
HTT P42858 3/20 0.51
LMNA P02545 3/20 0.51
NPY1R P25929 1/20 0.51
AKR1B10 O60218 1/20 0.48
AKR1B1 P15121 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8345935 0.93 MEN1 (0.59) MAPTMEN1KMT2AALDH1A1NPSR1
SCHEMBL6718734 0.90 MAPT (0.61) MAPTMEN1KMT2AALDH1A1NPSR1
SCHEMBL6717586 0.89 MEN1 (0.49) MAPTMEN1KMT2AALDH1A1NPSR1
SCHEMBL6716886 0.88 MAPT (0.58) MAPTMEN1KMT2AALDH1A1NPSR1
SCHEMBL6719450 0.88 MAPT (0.57) MAPTMEN1KMT2AALDH1A1NPSR1
SCHEMBL6715692 0.87 MEN1 (0.55) MAPTMEN1KMT2AALDH1A1NPSR1
SCHEMBL6723621 0.86 MEN1 (0.57) MAPTMEN1KMT2AALDH1A1NPSR1
SCHEMBL6715664 0.86 MEN1 (0.56) MAPTMEN1KMT2AALDH1A1NPSR1
SCHEMBL8347861 0.86 MEN1 (0.56) MAPTMEN1KMT2AALDH1A1NPSR1
SCHEMBL6715739 0.84 MEN1 (0.56) MAPTMEN1KMT2AALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 MAPT 427/4885MEN1 2933/4885KMT2A 2020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.